Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

1.9K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

118
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
118

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AAV-mediated delivery of CRISPR/Cas9 targeting conserved overlapping ORFs efficiently suppresses HBV replication in hepatocyte models.

Biotechnology reports (Amsterdam, Netherlands)·2026
Same author

Epstein-Barr virus-specific T-cells in pediatric liver transplant recipients.

Scientific reports·2026
Same author

Outcomes of hematopoietic stem cell transplantation for pediatric patients with transfusion-dependent thalassemia in Thailand.

Clinical and experimental pediatrics·2026
Same author

Biologically Distinct, Clinically Convergent: A Comparative Study of Umbilical Cord- and Adipose-Derived Mesenchymal Stem Cell Exosomes in Human Skin Regeneration.

Aesthetic surgery journal·2026
Same author

Identifying GFAP-expressing cell susceptibility to SARS-CoV-2 infection using human iPSC-derived neural cells.

Scientific reports·2026
Same author

Transcriptomic Correlation Identifies Cell Model Representatives for <i>MYCN</i>-Amplified Pediatric Neuroblastoma, Downstream Impact of Model Choice on Functional Interpretation, and Potential Drug Repositioning Candidates.

Omics : a journal of integrative biology·2026

Related Experiment Video

Updated: Oct 18, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K

Curcumin inhibited hepatitis B viral entry through NTCP binding.

Piyanoot Thongsri1,2, Yongyut Pewkliang1,2, Suparerk Borwornpinyo3,4

  • 1Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand.

Scientific Reports
|September 28, 2021
PubMed
Summary

Curcumin (CCM) effectively inhibits Hepatitis B virus (HBV) entry by targeting the NTCP receptor. This discovery offers a new strategy to suppress HBV infection and prevent reinfection.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.5K

Related Experiment Videos

Last Updated: Oct 18, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.5K

Area of Science:

  • Hepatology
  • Virology
  • Natural Product Chemistry

Background:

  • Hepatitis B virus (HBV) causes liver disease and cancer.
  • Current treatments only attenuate HBV infection, highlighting the need for novel strategies.
  • Targeting multiple stages of the viral life cycle, including entry, is crucial for eradication.

Purpose of the Study:

  • To investigate the inhibitory potential of Curcumin (CCM) against HBV attachment and internalization.
  • To elucidate the mechanism of CCM's action on HBV entry.
  • To assess CCM's efficacy in reducing viral markers and its interaction with the HBV receptor.

Main Methods:

  • HepaRG cells and immortalized hepatocyte-like cells (imHCs) were used for binding studies.
  • Viral load, HBeAg, HBcAg, intracellular HBV DNA, and cccDNA levels were quantified.
  • Sodium-taurocholate co-transporting polypeptide (NTCP) density and its correlation with CCM's effect were analyzed.
  • Taurocholic acid (TCA) uptake assays and isothermal titration calorimetry (ITC) were employed to determine the site and affinity of CCM action.

Main Results:

  • CCM significantly reduced HBV viral load, HBeAg, HBcAg, intracellular HBV DNA, and cccDNA.
  • The suppression of HBV entry by CCM was directly correlated with host cell NTCP receptor density.
  • CCM was confirmed to act on the HBV entry pathway, with measured affinity for NTCP.

Conclusions:

  • Curcumin (CCM) effectively inhibits Hepatitis B virus (HBV) entry by interacting with the NTCP receptor.
  • CCM demonstrates potential as a therapeutic agent to suppress HBV infection and prevent viral reinfection.
  • Targeting HBV entry with compounds like CCM represents a promising strategy for novel antiviral therapies.